Alnylam Pharmaceuticals (NASDAQ:ALNY) Releases Quarterly Earnings Results

Alnylam Pharmaceuticals (NASDAQ:ALNY) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported $0.82 earnings per share for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.61), Briefing.com reports. The business had revenue of $1.10 billion during the quarter, compared to analyst estimates of $1.16 billion. Alnylam Pharmaceuticals had a return on equity of 26.61% and a net margin of 1.36%.The firm’s revenue for the quarter was up 84.9% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.65) EPS.

Here are the key takeaways from Alnylam Pharmaceuticals’ conference call:

• GAAP profitability: Alnylam achieved GAAP profitability for full‑year 2025 and reported nearly $3.0 billion in combined net product revenues (81% YoY), with the AMVUTTRA ATTR‑CM launch cited as the primary driver.
• 2026 guidance and 2030 goals: The company reiterated 2026 combined product sales guidance of $4.9–$5.3 billion (TTR $4.4–$4.7B) and launched “Alnylam 2030” targets aiming for global TTR leadership, >25% revenue CAGR to 2030 and ~30% non‑GAAP operating margin through 2030.
• AMVUTTRA launch dynamics: Early U.S. uptake is strong—approaching parity with tafamidis in new starts and >90% payer first‑line coverage—however management flagged expected Q1 2026 headwinds from German pricing adjustments, seasonality and a mid‑single‑digit net price decline assumption.
• Pipeline and platform progress: Alnylam initiated three Phase‑3 trials (ZENITH for zilebesiran; TRITON‑CM and TRITON‑PN for nucresiran), added four new Alnylam clinical programs (e.g., ACVR1C and MAPT) and launched the Syrelis enzymatic ligation manufacturing platform to expand capacity and lower COGS.
• Near‑term financial headwinds: Gross margin declined to 77% in 2025 due to higher royalties (Sanofi), 2026 collaboration/royalty revenue guidance is down (no repeat of the $300M milestone), and the company anticipates continued net price pressure in the U.S.

Alnylam Pharmaceuticals Price Performance

Alnylam Pharmaceuticals stock traded down $15.75 during mid-day trading on Thursday, hitting $306.53. 1,266,863 shares of the company were exchanged, compared to its average volume of 1,581,118. The company has a debt-to-equity ratio of 4.45, a current ratio of 2.54 and a quick ratio of 2.49. The company has a market capitalization of $40.50 billion, a P/E ratio of 1,269.54 and a beta of 0.35. The business’s 50 day simple moving average is $380.99 and its two-hundred day simple moving average is $424.91. Alnylam Pharmaceuticals has a 12-month low of $205.87 and a 12-month high of $495.55.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, EVP Tolga Tanguler sold 1,510 shares of the stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $362.87, for a total transaction of $547,933.70. Following the transaction, the executive vice president owned 29,728 shares of the company’s stock, valued at $10,787,399.36. This trade represents a 4.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Pushkal Garg sold 1,510 shares of the business’s stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $362.87, for a total value of $547,933.70. Following the sale, the executive vice president owned 22,511 shares of the company’s stock, valued at $8,168,566.57. The trade was a 6.29% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 31,305 shares of company stock worth $12,459,785 over the last ninety days. Insiders own 1.50% of the company’s stock.

Institutional Trading of Alnylam Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. Bank of Montreal Can boosted its holdings in shares of Alnylam Pharmaceuticals by 253.5% in the 4th quarter. Bank of Montreal Can now owns 35,116 shares of the biopharmaceutical company’s stock valued at $13,964,000 after buying an additional 25,183 shares during the period. HM Payson & Co. bought a new position in shares of Alnylam Pharmaceuticals during the fourth quarter valued at approximately $27,000. denkapparat Operations GmbH bought a new position in shares of Alnylam Pharmaceuticals during the fourth quarter valued at approximately $363,000. Colonial Trust Co SC lifted its holdings in shares of Alnylam Pharmaceuticals by 160.5% in the 4th quarter. Colonial Trust Co SC now owns 99 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 61 shares during the last quarter. Finally, Principal Securities Inc. boosted its position in Alnylam Pharmaceuticals by 7.7% during the 4th quarter. Principal Securities Inc. now owns 2,626 shares of the biopharmaceutical company’s stock valued at $1,044,000 after purchasing an additional 188 shares during the period. 92.97% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have issued reports on ALNY. Bank of America decreased their price target on Alnylam Pharmaceuticals from $529.00 to $462.00 and set a “buy” rating for the company in a report on Friday, January 30th. Stifel Nicolaus upped their price objective on Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the company a “buy” rating in a report on Thursday, December 11th. Oppenheimer began coverage on shares of Alnylam Pharmaceuticals in a research note on Wednesday, January 7th. They issued an “outperform” rating and a $500.00 price target for the company. Royal Bank Of Canada decreased their price target on Alnylam Pharmaceuticals from $500.00 to $465.00 and set an “outperform” rating for the company in a report on Tuesday, January 20th. Finally, Jefferies Financial Group reduced their price target on shares of Alnylam Pharmaceuticals from $550.00 to $549.00 and set a “buy” rating for the company in a research report on Thursday, October 30th. Twenty-two investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $477.13.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.